Marguerite Davis is a clinical data analyst at Foresite Capital and contributes to due diligence and research and development evaluation of investment opportunities. She joined the investment team in 2022.
Marguerite brings scientific expertise, project and alliance management experience from both academia and industry to Foresite Capital. In her prior role as R&D Operations Director at Cabaletta Bio, she managed several cross-functional teams spanning labs at PENN and Cabaletta, commercial manufacturing facilities and clinical sites and supported regulatory submissions for autologous cell therapies for auto-immune disease. Previously, she spent five years as senior project manager for a wide range of rare disease focused programs at the Gene Therapy Program within University of Pennsylvania. She implemented nonclinical partnerships, regulatory submissions and early BD for multiple emergent start-up gene therapy companies including RegenxBio and Passage Bio.
She earned a PhD from the Chemistry and Biochemistry Department at University of Delaware and completed postdoctoral studies within the Department of Pharmacology and Physiology at Drexel University. Her research focused on the role of mRNA degradation in injury-induced regeneration of the peripheral nervous system and microRNAs as biomarkers and therapeutics in inflammatory and neuropathic pain.